{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:45Z","timestamp":1783577745030,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      As a classic botanical drug,\n                      <jats:italic>Salvia miltiorrhiza<\/jats:italic>\n                      Bunge has long been used to promote blood circulation and remove blood stasis. Tanshinone IIA (Tan IIA), a major bioactive diterpenoid derived from its roots, shows promising therapeutic potential, but its chemopreventive actions against early tumor progression have not been fully clarified. This study aims to comprehensively examine the chemopreventive potential of Tan IIA, specifically focusing on the poorly studied adenoma-to-early-carcinoma transition in breast cancer, and elucidate its underlying anti-angiogenic mechanisms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We adopted the mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT) transgenic mouse model, which recapitulates the natural progression of spontaneous breast tumorigenesis. A combination of pharmacokinetic analysis, network pharmacology,\n                      <jats:italic>in vivo<\/jats:italic>\n                      histopathology, immunofluorescence (IF) staining, multiple angiogenesis assays, and molecular experiments, including qPCR, Western blot, and cellular thermal shift assay (CETSA), was applied for comprehensive evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our results demonstrated that Tan IIA markedly delayed the malignant transformation of benign mammary tumors. Pharmacokinetic characterization confirmed the favorable\n                      <jats:italic>in vivo<\/jats:italic>\n                      bioavailability of Tan IIA and its metabolites. Mechanistically, Tan IIA significantly downregulated tissue factor (TF), a critical driver of tumor angiogenesis. This reduction in TF expression was accompanied by decreased levels of vascular endothelial growth factor A (VEGFA) and other pro-angiogenic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our work reveals that Tan IIA exerts prominent chemopreventive effects against breast precancerous lesions, mainly by suppressing TF-mediated angiogenesis, indicating its great promise as a candidate agent for early breast cancer intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1848311","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:41Z","timestamp":1783575341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tanshinone IIA inhibits malignant progression in a spontaneous breast cancer mouse model by attenuating tissue factor-mediated angiogenesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Yan","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Sun","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Mao","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyue","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junde","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoman","family":"Li","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Lu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]},{"name":"State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology","place":["Taipa, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102749","DOI":"10.1016\/j.ctrv.2024.102749","article-title":"Havoc in harmony: unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment","volume":"127","author":"Acharya","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"156702","DOI":"10.1016\/j.phymed.2025.156702","article-title":"Tanshinone IIA promotes ferroptosis in cutaneous melanoma via STAT1-mediated upregulation of PTGS2 expression","volume":"141","author":"Chen","year":"2025","journal-title":"Phytomedicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1038\/s12276-025-01571-5","article-title":"Single-cell transcriptomics of the myeloid milieu reveals an angiogenic niche in triple-negative breast cancer","volume":"57","author":"Choi","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1505672","DOI":"10.3389\/fphar.2025.1505672","article-title":"Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms","volume":"16","author":"Ding","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"611087","DOI":"10.3389\/fphar.2020.611087","article-title":"Tanshinone IIA: a review of its anticancer effects","volume":"11","author":"Fang","year":"2021","journal-title":"Front. Pharmacology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1186\/s40001-025-02842-7","article-title":"Tanshinone IIA induces ferroptosis in colorectal cancer cells through the suppression of SLC7A11 expression via the PI3K\/AKT\/mTOR pathway","volume":"30","author":"Ge","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1055\/s-0039-1687894","article-title":"Tissue factor and cancer: regulation, tumor growth, and metastasis","volume":"45","author":"Hisada","year":"2019","journal-title":"Seminars Thrombosis Hemostasis"},{"key":"B8","first-page":"1975","volume-title":"SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. SEER Cancer Statistics Review","author":"Howlader","year":"2013"},{"key":"B9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1245\/s10434-026-19380-z","article-title":"Tissue factor as a prognostic and therapeutic biomarker in resected pancreatic cancer","volume":"33","author":"Kamiya","year":"2026","journal-title":"Ann. Surg. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jare.2024.04.009","article-title":"Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer","volume":"69","author":"Luo","year":"2025","journal-title":"J. Adv. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2174\/1568026622666220308161710","article-title":"Vascular endothelial growth factor receptors [VEGFR] as target in breast cancer treatment: current status in preclinical and clinical studies and future directions","volume":"22","author":"Mohammad","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.20892\/j.issn.2095-3941.2023.0515","article-title":"Research progress in tumor angiogenesis and drug resistance in breast cancer","volume":"21","author":"Mou","year":"2024","journal-title":"Cancer Biol. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"9077926","DOI":"10.1155\/2024\/9077926","article-title":"Role of angiogenesis and its biomarkers in development of targeted tumor therapies","volume":"2024","author":"Pathak","year":"2024","journal-title":"Stem Cells Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.phymed.2009.08.010","article-title":"Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression","volume":"17","author":"Ren","year":"2010","journal-title":"Phytomedicine"},{"key":"B17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jare.2024.04.029","article-title":"Tanshinone IIA alleviates pulmonary fibrosis by modulating glutamine metabolic reprogramming based on [U-(13)C(5)]-glutamine metabolic flux analysis","volume":"70","author":"Shan","year":"2025","journal-title":"J. Adv. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B19","doi-asserted-by":"publisher","first-page":"10223","DOI":"10.1007\/s00210-026-05042-0","article-title":"Przewaquinone A regulates cell cycle and autophagy through the SrC\/STAT3 signaling pathway to inhibit colorectal cancer progression","volume":"399","author":"Su","year":"2026","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-020-00932-z","article-title":"Beyond thrombosis: the impact of tissue factor signaling in cancer","volume":"13","author":"Unruh","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1016\/j.ajpath.2014.07.027","article-title":"Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression","volume":"184","author":"Wu","year":"2014","journal-title":"Am. J. Pathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"105177","DOI":"10.1016\/j.micinf.2023.105177","article-title":"Protective effects of tanshinone IIA on porphyromonas gingivalis-induced atherosclerosis via the downregulation of the NOX2\/NOX4-ROS mediation of NF-\u03baB signaling pathway","volume":"25","author":"Xuan","year":"2023","journal-title":"Microbes Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000525055","article-title":"Tanshinone IIA inhibits tissue factor expression induced by thrombin in human umbilical vein endothelial cells via PAR-1 and p38 MAPK signaling pathway","volume":"145","author":"Zhang","year":"2022","journal-title":"Acta Haematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"114465","DOI":"10.1016\/j.intimp.2025.114465","article-title":"Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via down-regulation of MAPKs\/NF-\u03baB signaling pathway","volume":"152","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s12672-025-03797-1","article-title":"Microenvironmental regulation and remodeling of breast cancer angiogenesis: from basic mechanisms to clinical therapeutic implications","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:42Z","timestamp":1783575342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1848311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":26,"alternative-id":["10.3389\/fphar.2026.1848311"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1848311","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1848311"}}